公开(公告)号：US20230090176A1

公开(公告)日：2023-03-23

申请号：US17850875

申请日：2022-06-27

申请人： Juno Therapeutics, Inc.

发明人： Chris RAMSBORG ,  Mark L. BONYHADI ,  Calvin CHAN ,  Pascal BEAUCHESNE

IPC分类号： A61K35/17 ,  B01D15/38 ,  C12N5/10 ,  C12N5/0783 ,  C12M1/00

摘要： The present disclosure relates in some aspects to methods, cells, and compositions for preparing cells and compositions for genetic engineering and cell therapy. Provided in some embodiments are streamlined cell preparation methods, e.g., for isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are cells and compositions produced by the methods and methods of their use. The cells can include immune cells, such as T cells, and generally include a plurality of isolated T cell populations or types. In some aspects, the methods arc capable of preparing of a plurality of different cell populations for adoptive therapy using fewer steps and/or resources and/or reduced handling compared with other methods.

公开(公告)号：US20240158837A1

公开(公告)日：2024-05-16

申请号：US18488850

申请日：2023-10-17

申请人： Juno Therapeutics, Inc.

发明人： Mark L. BONYHADI ,  David G. KUGLER ,  Timothy G. JOHNSTONE ,  Ronald James HAUSE, Jr. ,  Lucas J. THOMPSON ,  Ryan P. LARSON

IPC分类号： C12Q1/6827 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  G16B20/10 ,  G16B20/20 ,  G16B30/10 ,  G16B40/10

CPC分类号： C12Q1/6827 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  G16B20/10 ,  G16B20/20 ,  G16B30/10 ,  G16B40/10 ,  C12Q2600/142 ,  C12Q2600/154 ,  C12Q2600/156

摘要： Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic analyses of the cells in connection with methods for preparing engineered cells for cell therapy and/or predicting response to a cell therapy, e.g., engineered cells for cell therapy. In some embodiments, the methods include steps to assess, characterize and analyze changes or modifications in an epigenetic property of gene region or regions, such as chromatin accessibility, nucleosome occupancy, histone modification, spatial chromosomal conformation, transcription factor occupancy and/or DNA methylation. In some embodiments, the epigenetic and/or epigenomic analysis includes determining the epigenetic properties of a cell, e.g., an engineered cell for cell therapy.

公开(公告)号：US20200297760A1

公开(公告)日：2020-09-24

申请号：US15780624

申请日：2016-12-02

申请人： Juno Therapeutics, Inc.

发明人： Mark L. BONYHADI

IPC分类号： A61K35/12 ,  C07K14/725 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  A61P35/00 ,  C07K14/705

摘要： Provided are methods of administering peptides containing portions of or corresponding to an agent to be administered, such as a cell or molecule expressed by such cell such as a recombinant protein such as a chimeric receptor. In some embodiments, the administration is in conjunction with treatment methods employing the agent, e.g., cell or chimeric receptor, such as adoptive cell therapy methods. The chimeric receptor can be a chimeric antigen receptor (CAR). The peptides contain an epitope of the recombinant receptor and, in some embodiments, are capable of downregulating or reducing immune responses against the chimeric receptor, such as CAR. Also provided are such peptides and compositions that can induce tolerance to an agent such as a chimeric receptor, such as a CAR.

公开(公告)号：US20230190814A1

公开(公告)日：2023-06-22

申请号：US18166447

申请日：2023-02-08

申请人： Juno Therapeutics, Inc.

发明人： Chris RAMSBORG ,  Mark L. BONYHADI ,  Calvin CHAN ,  Pascal BEAUCHESNE

IPC分类号： A61K35/17 ,  C12N5/10 ,  B01D15/38 ,  C12M1/00 ,  C12N5/0783

CPC分类号： A61K35/17 ,  C12N5/10 ,  B01D15/3804 ,  C12M47/04 ,  C12N5/0636 ,  G01N2333/70514 ,  A61K2035/124

摘要： The present disclosure relates in some aspects to methods, cells, and compositions for preparing cells and compositions for genetic engineering and cell therapy. Provided in some embodiments are streamlined cell preparation methods, e.g., for isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are cells and compositions produced by the methods and methods of their use. The cells can include immune cells, such as T cells, and generally include a plurality of isolated T cell populations or types. In some aspects, the methods are capable of preparing of a plurality of different cell populations for adoptive therapy using fewer steps and/or resources and/or reduced handling compared with other methods.

公开(公告)号：US20200239910A1

公开(公告)日：2020-07-30

申请号：US16637447

申请日：2018-08-09

申请人： Juno Therapeutics, Inc.

发明人： Mark L. BONYHADI

IPC分类号： C12N15/86 ,  C12N5/0783 ,  A61K35/17

摘要： Provided are methods for preparing T cells for cell therapy, compositions produced by the methods, and methods of administering the cells to subjects. In particular, the disclosure relates to preparation of engineered T cells, such as those expressing genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or lower toxicity compared with other methods. The provided methods include incubating cells under stimulating conditions to induce expansion or proliferation of naive-like T cells compared to non-naive like T cells in the stimulated composition, which in turn can result in preferential transduction of cells derived from the naive-like T cells. Features of the methods can also include reduction in costs, numbers of steps, and resource expenditure compared with other methods.

公开(公告)号：US20170037369A1

公开(公告)日：2017-02-09

申请号：US15305337

申请日：2015-04-23

申请人： JUNO THERAPEUTICS, INC.

发明人： Chris RAMSBORG ,  Mark L. BONYHADI ,  Calvin CHAN ,  Pascal BEAUCHESNE

IPC分类号： C12N5/0783 ,  G01N33/569 ,  A61K35/17 ,  C12M1/00

摘要： The present disclosure relates in some aspects to methods, cells, and compositions for preparing cells and compositions for genetic engineering and cell therapy. Provided in some embodiments are streamlined cell preparation methods, e.g., for isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are cells and compositions produced by the methods and methods of their use. The cells can include immune cells, such as T cells, and generally include a plurality of isolated T cell populations or types. In some aspects, the methods are capable of preparing of a plurality of different cell populations for adoptive therapy using fewer steps and/or resources and/or reduced handling compared with other methods.

摘要翻译： 本公开在一些方面涉及用于制备用于基因工程和细胞治疗的细胞和组合物的方法，细胞和组合物。 在一些实施方案中提供了流线型的细胞制备方法，例如用于细胞和细胞群体的分离，加工，孵育和遗传工程。 还提供了通过其使用的方法和方法制备的细胞和组合物。 细胞可以包括免疫细胞，例如T细胞，并且通常包括多个分离的T细胞群体或类型。 在一些方面，与其他方法相比，该方法能够使用更少的步骤和/或资源和/或减少的处理来制备用于过继治疗的多个不同细胞群体。